|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Attard G, Parker C, Eeles RA, Schröder F,
Tomlins SA, Tannock I, Drake CG and de Bono JS: Prostate cancer.
Lancet. 387:70–82. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perner S, Cronauer MV, Schrader AJ,
Klocker H, Culig Z and Baniahmad A: Adaptive responses of androgen
receptor signaling in castration-resistant prostate cancer.
Oncotarget. 6:35542–35555. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saad F and Fizazi K: Androgen deprivation
therapy and secondary hormone therapy in the management of
hormone-sensitive and castration-resistant prostate cancer.
Urology. 86:852–861. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nguyen PL, Alibhai SM, Basaria S, D'Amico
AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B and
Smith MR: Adverse effects of androgen deprivation therapy and
strategies to mitigate them. Eur Urol. 67:825–836. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tagawa ST, Posadas EM, Bruce J, Lim EA,
Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, et al:
Phase 1b study of abiraterone acetate plus prednisone and docetaxel
in patients with metastatic castration-resistant prostate cancer.
Eur Urol. 70:718–721. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Teply BA, Luber B, Denmeade SR and
Antonarakis ES: The influence of prednisone on the efficacy of
docetaxel in men with metastatic castration-resistant prostate
cancer. Prostate Cancer Prostatic Dis. 19:72–78. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nishimura K, Nonomura N, Satoh E, Harada
Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, et al:
Potential mechanism for the effects of dexamethasone on growth of
androgen-independent prostate cancer. J Natl Cancer Inst.
93:1739–1746. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yemelyanov A, Czwornog J, Chebotaev D,
Karseladze A, Kulevitch E, Yang X and Budunova I: Tumor suppressor
activity of glucocorticoid receptor in the prostate. Oncogene.
26:1885–1896. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arora VK, Schenkein E, Murali R, Subudhi
SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis
C, et al: Glucocorticoid receptor confers resistance to
antiandrogens by bypassing androgen receptor blockade. Cell.
155:1309–1322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Isikbay M, Otto K, Kregel S, Kach J, Cai
Y, Vander Griend DJ, Conzen SD and Szmulewitz RZ: Glucocorticoid
receptor activity contributes to resistance to androgen-targeted
therapy in prostate cancer. Horm Cancer. 5:72–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Narayanan S, Srinivas S and Feldman D:
Androgen-glucocorticoid interactions in the era of novel prostate
cancer therapy. Nat Rev Urol. 13:47–60. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie N, Cheng H, Lin D, Liu L, Yang O, Jia
L, Fazli L, Gleave ME, Wang Y, Rennie P and Dong X: The expression
of glucocorticoid receptor is negatively regulated by active
androgen receptor signaling in prostate tumors. Int J Cancer.
136:E27–E38. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Venkitaraman R, Lorente D, Murthy V,
Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J
and Parker C: A randomised phase 2 trial of dexamethasone versus
prednisolone in castration-resistant prostate cancer. Eur Urol.
67:673–679. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu J and Chen Q: The role of
glucocorticoid receptor in prostate cancer progression: From bench
to bedside. Int Urol Nephrol. 49:369–380. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song C, Kim Y, Min GE and Ahn H:
Dihydrotestosterone enhances castration-resistant prostate cancer
cell proliferation through STAT5 activation via glucocorticoid
receptor pathway. Prostate. 74:1240–1248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wen S, Shang Z, Zhu S, Chang C and Niu Y:
Androgen receptor enhances entosis, a non-apoptotic cell death,
through modulation of Rho/ROCK pathway in prostate cancer cells.
Prostate. 73:1306–1315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kan SF, Huang WJ, Lin LC and Wang PS:
Inhibitory effects of evodiamine on the growth of human prostate
cancer cell line LNCaP. Int J Cancer. 110:641–651. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu KK: Analysis of protein-DNA binding by
streptavidin-agarose pulldown. Methods Mol Biol. 338:281–290.
2006.PubMed/NCBI
|
|
20
|
Ramamoorthy S and Cidlowski JA: Exploring
the molecular mechanisms of glucocorticoid receptor action from
sensitivity to resistance. Endocr Dev. 24:41–56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan S, Trachtenberg J, Mills GB, Brown
TJ, Xu F and Keating A: Androgen-induced inhibition of cell
proliferation in an androgen-insensitive prostate cancer cell line
(PC-3) transfected with a human androgen receptor complementary
DNA. Cancer Res. 53:1304–1311. 1993.PubMed/NCBI
|
|
22
|
Hu J, Wang G and Sun T: Dissecting the
roles of the androgen receptor in prostate cancer from molecular
perspectives. Tumour Biol. 39:10104283176922592017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paliouras M and Diamandis EP: An AKT
activity threshold regulates androgen-dependent and
androgen-independent PSA expression in prostate cancer cell lines.
Biol Chem. 389:773–780. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yano A, Fujii Y, Iwai A, Kageyama Y and
Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo
growth of prostate cancer cells. Clin Cancer Res. 12:3003–3009.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Attardi BJ, Burgenson J, Hild SA and Reel
JR: Steroid hormonal regulation of growth, prostate specific
antigen secretion, and transcription mediated by the mutated
androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol
Cell Endocrinol. 222:121–132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hartig SM, He B, Newberg JY, Ochsner SA,
Loose DS, Lanz RB, McKenna NJ, Buehrer BM, McGuire SE, Marcelli M
and Mancini MA: Feed-forward inhibition of androgen receptor
activity by glucocorticoid action in human adipocytes. Chem Biol.
19:1126–1141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stechschulte LA and Sanchez ER: FKBP51-a
selective modulator of glucocorticoid and androgen sensitivity.
Curr Opin Pharmacol. 11:332–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jääskeläinen T, Makkonen H and Palvimo JJ:
Steroid up-regulation of FKBP51 and its role in hormone signaling.
Curr Opin Pharmacol. 11:326–331. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Storlie JA, Buckner JC, Wiseman GA, Burch
PA, Hartmann LC and Richardson RL: Prostate specific antigen levels
and clinical response to low dose dexamethasone for
hormone-refractory metastatic prostate carcinoma. Cancer.
76:96–100. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nishimura K, Nonomura N, Yasunaga Y,
Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T and
Okuyama A: Low doses of oral dexamethasone for hormone-refractory
prostate carcinoma. Cancer. 89:2570–2576. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morioka M, Kobayashi T, Furukawa Y, Jo Y,
Shinkai M, Matsuki T, Yamamoto T and Tanaka H: Prostate-specific
antigen levels and prognosis in patients with hormone-refractory
prostate cancer treated with low-dose dexamethasone. Urol Int.
68:10–15. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Venkitaraman R, Thomas K, Huddart RA,
Horwich A, Dearnaley DP and Parker CC: Efficacy of low-dose
dexamethasone in castration-refractory prostate cancer. BJU Int.
101:440–443. 2008.PubMed/NCBI
|
|
33
|
Kume H, Suzuki M, Fujimura T, Fukuhara H,
Enomoto Y, Nishimatsu H, Ishikawa A and Homma Y: Docetaxel as a
vital option for corticosteroid-refractory prostate cancer. Int
Urol Nephrol. 43:1081–1087. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shamash J, Powles T, Sarker SJ, Protheroe
A, Mithal N, Mills R, Beard R, Wilson P, Tranter N, O'Brien N, et
al: A multi-centre randomised phase III trial of dexamethasone vs
dexamethasone and diethylstilbestrol in castration-resistant
prostate cancer: Immediate vs deferred diethylstilbestrol. Br J
Cancer. 104:620–628. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hodson R: Small organ, big reach. Nature.
528:S118–S119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zheng Y, Izumi K, Li Y, Ishiguro H and
Miyamoto H: Contrary regulation of bladder cancer cell
proliferation and invasion by dexamethasone-mediated glucocorticoid
receptor signals. Mol Cancer Ther. 11:2621–2632. 2012. View Article : Google Scholar : PubMed/NCBI
|
